Home
About
Overview
Sharing Data
ORCID
Help
History (10)
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Principal Investigator
Principal Investigator
Principal Investigator
See All 10 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Principal Investigator
Overview
researcher role of
Small, Stephen
contributes to
HEALTHCARE SIMULATION: TRAINING, ASSESSMENT AND RESEARCH